Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Trading Statement

28 Mar 2006 07:00

Celsis International PLC28 March 2006 CELSIS INTERNATIONAL PLC Pre-Close Trading Update 28 March 2006: Celsis International plc ("Celsis" or the "Company"), the rapidmicrobial detection and analytical services company, today announces an updateon trading prior to the close of its financial year. The Company has made good progress in the year, especially from strong secondhalf performance from the Laboratory Group. The Product Group continues toperform well and as a result, the company is on track to announce profits inline with the Board's expectations for the year ended 31 March 2006. Celsis will announce its preliminary results for the year ended 31 March 2006,on Wednesday 14 June 2006. There will be a presentation to analysts on the dayat 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings,London, WC2A 1PB. Jay LeCoque, Chief Executive Officer, of Celsis International plc commented: "Celsis has continued to see healthy trading in the second half of the year andI am pleased to report that the Company is set to report another set of year endresults that are in line with Board expectations. Our Laboratory Group strategyto focus on higher margin services has been particularly successful during thesecond half of the year and we expect this business to continue to grow morestrongly into our new fiscal year. The Product Group remains the leader in its selected fields of interest andcontinues to benefit from Celsis' unmatched global presence, which we believe tobe a significant advantage as we grow this business further. Overall, Celsis ison track to retain its high levels of profitability and we are very confidentabout the Company's future prospects to develop the business both organicallyand through acquisition opportunities." Enquiries:Celsis International plc Tel: 01638 600 151Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate CommunicationsFinancial Dynamics Tel: 020 7831 3113 Ben AtwellDavid Yates Notes to editors Celsis International plc Celsis International plc is a rapid microbial detection and analytical servicescompany. The company is listed on the London Stock Exchange (CEL.L). Using proprietary technology, the Product Group is the world leader in theprovision of diagnostic systems for the rapid detection of microbialcontamination. It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical and biopharmaceuticalcompanies to ensure the stability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisionshave the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.